SJH-CHS_NRG-BR003 (16-017)

NRG-BR003: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

Phase II
NCT02488967
All Other|Cancer
Breast
Ibrahim Shalaby, M.D.
NRG (NRG Oncology)
Christy Ratheal
  • Covenant Health